Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 443

1.

Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.

Koh XY, Koh XH, Hwang LA, Ferrer FJ, Rahmat SAB, Lama D, Lane DP.

Oncogene. 2019 Aug 15. doi: 10.1038/s41388-019-0946-8. [Epub ahead of print]

PMID:
31417186
2.

How to lose tumor suppression.

Lane DP.

Science. 2019 Aug 9;365(6453):539-540. doi: 10.1126/science.aay4319. No abstract available.

PMID:
31395768
3.

Intratumour heterogeneity of p53 expression; causes and consequences.

Xue Y, San Luis B, Lane DP.

J Pathol. 2019 Jul 19. doi: 10.1002/path.5328. [Epub ahead of print] Review.

PMID:
31322742
4.

Stereoisomerism of stapled peptide inhibitors of the p53-Mdm2 interaction: an assessment of synthetic strategies and activity profiles.

Yuen TY, Brown CJ, Xue Y, Tan YS, Ferrer Gago FJ, Lee XE, Neo JY, Thean D, Kaan HYK, Partridge AW, Verma CS, Lane DP, Johannes CW.

Chem Sci. 2019 May 30;10(26):6457-6466. doi: 10.1039/c9sc01456j. eCollection 2019 Jul 14.

5.

Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties.

Partridge AW, Kaan HYK, Juang YC, Sadruddin A, Lim S, Brown CJ, Ng S, Thean D, Ferrer F, Johannes C, Yuen TY, Kannan S, Aronica P, Tan YS, Pradhan MR, Verma CS, Hochman J, Chen S, Wan H, Ha S, Sherborne B, Lane DP, Sawyer TK.

Molecules. 2019 Jun 20;24(12). pii: E2292. doi: 10.3390/molecules24122292.

6.

p53: updates on mechanisms, biology and therapy (I).

Lane DP, Verma CS.

J Mol Cell Biol. 2019 Mar 1;11(3):185-186. doi: 10.1093/jmcb/mjz017. No abstract available.

PMID:
31222355
7.

p53: updates on mechanisms, biology and therapy (II).

Lane DP, Verma CS.

J Mol Cell Biol. 2019 Apr 1;11(4):265-266. doi: 10.1093/jmcb/mjz018. No abstract available.

PMID:
31222348
8.

Characterization of Hydration Properties in Structural Ensembles of Biomolecules.

Pradhan MR, Nguyen MN, Kannan S, Fox SJ, Kwoh CK, Lane DP, Verma CS.

J Chem Inf Model. 2019 Jul 22;59(7):3316-3329. doi: 10.1021/acs.jcim.8b00453. Epub 2019 Jun 17.

PMID:
31140800
9.

Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues In Vivo.

Xue Y, Barker N, Hoon S, He P, Thakur T, Abdeen SR, Maruthappan P, Ghadessy FJ, Lane DP.

Cancer Res. 2019 Jul 15;79(14):3595-3607. doi: 10.1158/0008-5472.CAN-18-3744. Epub 2019 May 28.

PMID:
31138526
10.

Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly.

Frosi Y, Usher R, Lian DTG, Lane DP, Brown CJ.

BMC Biol. 2019 May 22;17(1):40. doi: 10.1186/s12915-019-0658-0.

11.

Guardian of Genome Editing.

Ho T, Lane DP.

CRISPR J. 2018 Aug;1:258-260. doi: 10.1089/crispr.2018.29021.dal. No abstract available.

PMID:
31021215
12.

Understanding p53 functions through p53 antibodies.

Sabapathy K, Lane DP.

J Mol Cell Biol. 2019 Apr 1;11(4):317-329. doi: 10.1093/jmcb/mjz010.

13.

Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides.

Pal A, Neo K, Rajamani L, Ferrer FJ, Lane DP, Verma CS, Mortellaro A.

Sci Rep. 2019 Mar 20;9(1):4913. doi: 10.1038/s41598-019-41211-3.

14.

Structural insights reveal a recognition feature for tailoring hydrocarbon stapled-peptides against the eukaryotic translation initiation factor 4E protein.

Lama D, Liberatore AM, Frosi Y, Nakhle J, Tsomaia N, Bashir T, Lane DP, Brown CJ, Verma CS, Auvin S.

Chem Sci. 2019 Jan 7;10(8):2489-2500. doi: 10.1039/c8sc03759k. eCollection 2019 Feb 28.

15.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX.

Br J Cancer. 2019 Apr;120(7):728-745. doi: 10.1038/s41416-019-0405-x. Epub 2019 Feb 28.

PMID:
30816325
16.

Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket.

Pradhan MR, Siau JW, Kannan S, Nguyen MN, Ouaray Z, Kwoh CK, Lane DP, Ghadessy F, Verma CS.

Nucleic Acids Res. 2019 Feb 28;47(4):1637-1652. doi: 10.1093/nar/gky1314.

17.

Radiation-induced astrocyte senescence is rescued by Δ133p53.

Turnquist C, Beck JA, Horikawa I, Obiorah IE, Von Muhlinen N, Vojtesek B, Lane DP, Grunseich C, Chahine JJ, Ames HM, Smart DD, Harris BT, Harris CC.

Neuro Oncol. 2019 Mar 18;21(4):474-485. doi: 10.1093/neuonc/noz001.

PMID:
30615147
18.

Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function.

Lau SY, Siau JW, Sobota RM, Wang CI, Zhong P, Lane DP, Ghadessy FJ.

Protein Eng Des Sel. 2018 Jul 1;31(7-8):301-312. doi: 10.1093/protein/gzy018.

19.

Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive.

Keszei M, Record J, Kritikou JS, Wurzer H, Geyer C, Thiemann M, Drescher P, Brauner H, Köcher L, James J, He M, Baptista MA, Dahlberg CI, Biswas A, Lain S, Lane DP, Song W, Pütsep K, Vandenberghe P, Snapper SB, Westerberg LS.

J Clin Invest. 2018 Aug 31;128(9):4115-4131. doi: 10.1172/JCI64772. Epub 2018 Aug 20.

20.

The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.

Spiegelberg D, Mortensen AC, Lundsten S, Brown CJ, Lane DP, Nestor M.

Cancer Res. 2018 Sep 1;78(17):5084-5093. doi: 10.1158/0008-5472.CAN-18-0440. Epub 2018 Jul 19.

PMID:
30026328
21.
22.

Mass Spectrometry Reveals the Direct Action of a Chemical Chaperone.

Gault J, Lianoudaki D, Kaldmäe M, Kronqvist N, Rising A, Johansson J, Lohkamp B, Laín S, Allison TM, Lane DP, Marklund EG, Landreh M.

J Phys Chem Lett. 2018 Jul 19;9(14):4082-4086. doi: 10.1021/acs.jpclett.8b01817. Epub 2018 Jul 9.

23.

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S.

Nat Commun. 2018 May 22;9(1):2071. doi: 10.1038/s41467-018-04198-5.

24.

Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.

Ladds MJGW, Pastor-Fernández A, Popova G, van Leeuwen IMM, Eng KE, Drummond CJ, Johansson L, Svensson R, Westwood NJ, McCarthy AR, Tholander F, Popa M, Lane DP, McCormack E, McInerney GM, Bhatia R, Laín S.

PLoS One. 2018 Apr 23;13(4):e0195956. doi: 10.1371/journal.pone.0195956. eCollection 2018.

25.

Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges.

Sawyer TK, Partridge AW, Kaan HYK, Juang YC, Lim S, Johannes C, Yuen TY, Verma C, Kannan S, Aronica P, Tan YS, Sherborne B, Ha S, Hochman J, Chen S, Surdi L, Peier A, Sauvagnat B, Dandliker PJ, Brown CJ, Ng S, Ferrer F, Lane DP.

Bioorg Med Chem. 2018 Jun 1;26(10):2807-2815. doi: 10.1016/j.bmc.2018.03.008. Epub 2018 Mar 16.

PMID:
29598901
26.

Effect of VH-VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding.

Ling WL, Lua WH, Poh JJ, Yeo JY, Lane DP, Gan SK.

Front Immunol. 2018 Mar 12;9:469. doi: 10.3389/fimmu.2018.00469. eCollection 2018.

27.

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S.

Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3. Erratum in: Nat Commun. 2018 May 22;9(1):2071.

28.

p53 isoforms regulate premature aging in human cells.

von Muhlinen N, Horikawa I, Alam F, Isogaya K, Lissa D, Vojtesek B, Lane DP, Harris CC.

Oncogene. 2018 May;37(18):2379-2393. doi: 10.1038/s41388-017-0101-3. Epub 2018 Feb 12.

29.

Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase.

Costeira-Paulo J, Gault J, Popova G, Ladds MJGW, van Leeuwen IMM, Sarr M, Olsson A, Lane DP, Laín S, Marklund EG, Landreh M.

Cell Chem Biol. 2018 Mar 15;25(3):309-317.e4. doi: 10.1016/j.chembiol.2017.12.012. Epub 2018 Jan 18.

30.

Role of the N-terminal lid in regulating the interaction of phosphorylated MDMX with p53.

Chan JV, Ping Koh DX, Liu Y, Joseph TL, Lane DP, Verma CS, Tan YS.

Oncotarget. 2017 Dec 1;8(68):112825-112840. doi: 10.18632/oncotarget.22829. eCollection 2017 Dec 22.

31.

The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding.

Lua WH, Ling WL, Yeo JY, Poh JJ, Lane DP, Gan SK.

Sci Rep. 2018 Jan 15;8(1):718. doi: 10.1038/s41598-017-18892-9. Erratum in: Sci Rep. 2018 Jul 18;8(1):11110.

32.

Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine.

Hwang LA, Phang BH, Liew OW, Iqbal J, Koh XH, Koh XY, Othman R, Xue Y, Richards AM, Lane DP, Sabapathy K.

Cell Rep. 2018 Jan 2;22(1):299-312. doi: 10.1016/j.celrep.2017.11.112.

33.

Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids.

Chee SMQ, Wongsantichon J, Siau J, Thean D, Ferrer F, Robinson RC, Lane DP, Brown CJ, Ghadessy FJ.

PLoS One. 2017 Dec 11;12(12):e0189379. doi: 10.1371/journal.pone.0189379. eCollection 2017.

34.

Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations.

Yadahalli S, Li J, Lane DP, Gosavi S, Verma CS.

Sci Rep. 2017 Nov 15;7(1):15600. doi: 10.1038/s41598-017-15930-4.

35.

Evidence for allosteric effects on p53 oligomerization induced by phosphorylation.

Muller P, Chan JM, Simoncik O, Fojta M, Lane DP, Hupp T, Vojtesek B.

Protein Sci. 2018 Feb;27(2):523-530. doi: 10.1002/pro.3344. Epub 2017 Dec 8.

36.

A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53.

Wong JH, Alfatah M, Sin MF, Sim HM, Verma CS, Lane DP, Arumugam P.

BMC Biol. 2017 Nov 9;15(1):108. doi: 10.1186/s12915-017-0446-7.

37.

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Sabapathy K, Lane DP.

Nat Rev Clin Oncol. 2018 Jan;15(1):13-30. doi: 10.1038/nrclinonc.2017.151. Epub 2017 Sep 26. Review.

PMID:
28948977
38.

Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity.

Zheng S, Koh XY, Goh HC, Rahmat SAB, Hwang LA, Lane DP.

Cancer Res. 2017 Aug 15;77(16):4342-4354. doi: 10.1158/0008-5472.CAN-17-0424. Epub 2017 Jun 27.

39.

Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery.

Thean D, Ebo JS, Luxton T, Lee XC, Yuen TY, Ferrer FJ, Johannes CW, Lane DP, Brown CJ.

Sci Rep. 2017 May 11;7(1):1763. doi: 10.1038/s41598-017-01712-5.

40.

Exploiting the p53 Pathway for Therapy.

Cheok CF, Lane DP.

Cold Spring Harb Perspect Med. 2017 Mar 1;7(3). pii: a026310. doi: 10.1101/cshperspect.a026310. Review.

41.

Anatomy of Mdm2 and Mdm4 in evolution.

Tan BX, Liew HP, Chua JS, Ghadessy FJ, Tan YS, Lane DP, Coffill CR.

J Mol Cell Biol. 2017 Feb 1;9(1):3-15. doi: 10.1093/jmcb/mjx002. Review.

42.

Water-Bridge Mediates Recognition of mRNA Cap in eIF4E.

Lama D, Pradhan MR, Brown CJ, Eapen RS, Joseph TL, Kwoh CK, Lane DP, Verma CS.

Structure. 2017 Jan 3;25(1):188-194. doi: 10.1016/j.str.2016.11.006. Epub 2016 Dec 1.

43.

The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage.

Xue Y, Raharja A, Sim W, Wong ES, Rahmat SA, Lane DP.

Oncogene. 2017 Apr 6;36(14):2002-2013. doi: 10.1038/onc.2016.374. Epub 2016 Nov 21.

44.

Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design.

Tan YS, Reeks J, Brown CJ, Thean D, Ferrer Gago FJ, Yuen TY, Goh ET, Lee XE, Jennings CE, Joseph TL, Lakshminarayanan R, Lane DP, Noble ME, Verma CS.

J Phys Chem Lett. 2016 Sep 1;7(17):3452-7. doi: 10.1021/acs.jpclett.6b01525. Epub 2016 Aug 22.

45.

Stapled peptide design: principles and roles of computation.

Tan YS, Lane DP, Verma CS.

Drug Discov Today. 2016 Oct;21(10):1642-1653. doi: 10.1016/j.drudis.2016.06.012. Epub 2016 Jun 18. Review.

PMID:
27326912
46.

Reactivation of mutant p53: Constraints on mechanism highlighted by principal component analysis of the DNA binding domain.

Ouaray Z, ElSawy KM, Lane DP, Essex JW, Verma C.

Proteins. 2016 Oct;84(10):1443-61. doi: 10.1002/prot.25089. Epub 2016 Jul 26.

PMID:
27317883
47.

p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration.

Turnquist C, Horikawa I, Foran E, Major EO, Vojtesek B, Lane DP, Lu X, Harris BT, Harris CC.

Cell Death Differ. 2016 Sep 1;23(9):1515-28. doi: 10.1038/cdd.2016.37. Epub 2016 Apr 22.

48.

Long range recognition and selection in IDPs: the interactions of the C-terminus of p53.

Kannan S, Lane DP, Verma CS.

Sci Rep. 2016 Mar 31;6:23750. doi: 10.1038/srep23750.

49.

The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans.

Coffill CR, Lee AP, Siau JW, Chee SM, Joseph TL, Tan YS, Madhumalar A, Tay BH, Brenner S, Verma CS, Ghadessy FJ, Venkatesh B, Lane DP.

Genes Dev. 2016 Feb 1;30(3):281-92. doi: 10.1101/gad.274118.115. Epub 2016 Jan 21.

50.

Recognition Dynamics of p53 and MDM2: Implications for Peptide Design.

ElSawy KM, Lane DP, Verma CS, Caves LS.

J Phys Chem B. 2016 Jan 21;120(2):320-8. doi: 10.1021/acs.jpcb.5b11162. Epub 2016 Jan 11.

PMID:
26701330

Supplemental Content

Support Center